Stocks Industrials CTKB
NASDAQ · IndustrialsCytek Biosciences, Inc. (CTKB)
Cytek Biosciences, Inc. brought in $207.6M of revenue over the twelve months to September 30, 2026, up 5.5% from a year earlier. It posted a net loss of $81.2M. In fiscal 2025 capital spending exceeded operating cash flow by $8.8M. At September 30, 2026 it held $66.8M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on November 4, 2026.
Key facts about Cytek Biosciences, Inc.
- Net worth
- Cytek Biosciences, Inc. has a market value (market cap) of $757.8M at the latest share price, and shareholders' equity of $321.4M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $201.5M (+0.5% year on year), with a net loss of $66.5M. Over the 12 months to September 30, 2026: revenue $207.6M, net loss $81.2M.
- Cash flow
- In fiscal 2025 operations used $4.7M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on November 4, 2026 and covers the period to September 30, 2026. Open on SEC EDGAR
- Next earnings report
- Cytek Biosciences, Inc.'s next report is expected around January 12, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
What Cytek Biosciences, Inc. does
Cytek Biosciences, Inc. is registered with the SEC under industry code SIC 3826 (Laboratory Analytical Instruments). Its shares trade on NASDAQ under the ticker CTKB.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $201.5M | -$66.5M | n/a | -$8.8M |
| 2024 | $200.5M | -$6M | n/a | $21.9M |
| 2023 | $193M | -$12.1M | -$0.09 | $633K |
| 2022 | $164M | $2.5M | $0.02 | -$22M |
| 2021 | $128M | $3M | $0.00 | $266K |
| 2021 | $92.8M | $19.4M | $0.10 | $13.6M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where CTKB ranks in Industrials
Latest SEC filings
What Cytek Biosciences, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 4, 2026Quarterly report 10-Q · period to September 30, 2026Revenue rose 1.8% to $53.2M versus the same quarter last year; net loss of $6.1M.
- November 4, 2026
- November 3, 2026Passive stake changed SCHEDULE 13G/A
- September 29, 2026
- August 24, 2026
- August 6, 2026Passive stake changed SCHEDULE 13G/A
- August 5, 2026Quarterly report 10-Q · period to June 30, 2026Revenue rose 5.6% to $48.1M versus the same quarter last year; net loss of $12.2M.
- August 5, 2026
- August 4, 2026Passive stake (5% or more) SCHEDULE 13G
- July 15, 2026
Insider trades
What the people running Cytek Biosciences, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider bought or sold shares on the open market in the last 90 days. The 25 reported changes were pay in shares, option exercises, shares withheld for tax or gifts.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| August 18, 2026 | Muir Glenn PDirector | Exercised options | 3,086 | - |
| August 18, 2026 | Chin RichardDirector | Exercised options | 6,107 | - |
| August 18, 2026 | Holder MichaelDirector | Exercised options | 2,181 | - |
| August 18, 2026 | Jiang WenbinPRESIDENT AND CEO, Director | Exercised options | 11,781 | - |
| August 18, 2026 | Jiang WenbinPRESIDENT AND CEO, Director | Shares withheld for tax | 2,869 | $13.4K |
| August 18, 2026 | Jiang WenbinPRESIDENT AND CEO, Director | Exercised options | 22,100 | - |
| August 18, 2026 | Jiang WenbinPRESIDENT AND CEO, Director | Shares withheld for tax | 5,382 | $25.1K |
| August 18, 2026 | Jiang WenbinPRESIDENT AND CEO, Director | Exercised options | 29,002 | - |
Who owns CTKB
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Boston Partners13G, passive | 5.91% | August 4, 2026 |
| Millennium Management LLC13G, passive with 3 related filers | 5.6% | November 3, 2026 |
| Topline Capital Management, LLC13G, passive with 2 related filers | 5.3% | November 17, 2025 |
| Hillhouse Investment Management, Ltd.13G, passive | 5.1% | November 14, 2024 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 155 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| BlackRock, Inc. | 9,578,643 | -7,428,626 |
| Millennium Management LLC | 9,338,010 | +3,046,212 |
| Boston Partners | 7,660,943 | +1,858,170 |
| Hhlr Advisors, Ltd. | 6,657,030 | 0 |
| Topline Capital Management, LLC | 6,283,450 | -781,031 |
| Vanguard Capital Management LLC | 4,939,597 | +176,693 |
| Geode Capital Management, LLC | 3,059,573 | +225,618 |
| Dimensional Fund Advisors LP | 2,616,257 | -47,072 |
| State Street Corp | 2,566,121 | -1,557,627 |
| Goldman Sachs Group Inc | 2,167,515 | -177,220 |
| Royce & Associates LP | 2,081,579 | +439,211 |
| Russell Investments Group, Ltd. | 1,511,315 | +151,415 |
| Bank of America Corp | 1,315,332 | +306,278 |
| Vanguard Portfolio Management LLC | 1,141,592 | -1,170,266 |
| Charles Schwab Investment Management Inc | 1,073,253 | -31,348 |
| Northern Trust Corp | 1,003,294 | -1,899 |
| Arrowstreet Capital, Limited Partnership | 973,833 | +653,924 |
| Jane Street Group, LLC | 906,162 | new |
| Tudor Investment Corp ET AL | 837,913 | +517,198 |
| Aqr Capital Management LLC | 813,971 | -98,371 |
Insiders
11 insiders reported holding 11,011,566 shares in total, about $64.2M at the last price.
| Holder | Shares |
|---|---|
| Jiang WenbinPRESIDENT AND CEO, Director | 5,561,029 |
| Yan MingCHIEF TECHNOLOGY OFFICER, Director | 4,821,870 |
| Barnett ValerieCHIEF LEGAL OFFICER | 150,012 |
| McCombe William D.Chief Financial Officer | 134,693 |
| Ball JackDirector | 86,678 |
| Holder MichaelDirector | 62,875 |
| Imper VeraDirector | 59,679 |
| Neff Deborah JDirector | 59,679 |
| Busque PhilippeSVP, GLOBAL SALES AND SERVICES | 43,466 |
| Chin RichardDirector | 28,499 |
Questions about CTKB
What does Cytek Biosciences, Inc. do?
Cytek Biosciences, Inc. is a company in the Industrials sector, listed on NASDAQ as CTKB. Its shares trade on NASDAQ under the ticker CTKB.
What is Cytek Biosciences, Inc.'s net worth?
Cytek Biosciences, Inc. has a market value (market cap) of $757.8M at the latest share price, and shareholders' equity of $321.4M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Cytek Biosciences, Inc. profitable?
No. Over the twelve months to September 30, 2026 it reported a net loss of $81.2M on revenue of $207.6M.
How much revenue does Cytek Biosciences, Inc. make?
Over the twelve months to September 30, 2026 Cytek Biosciences, Inc. reported revenue of $207.6M. That is 5.5% more than a year earlier.
When did Cytek Biosciences, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on November 4, 2026. It covers the period to September 30, 2026.
When is Cytek Biosciences, Inc.'s next earnings report?
Cytek Biosciences, Inc.'s next report is expected around January 12, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare CTKB with
Follow CTKB
Get an email when Cytek Biosciences, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Cytek Biosciences, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.